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In this issue of the journal Alvarez and colleagues [1] describe pain and other non-
neurological adverse events in children with sickle cell anemia (SS) and previous stroke who 
received hydroxyurea and phlebotomy or standard therapy with chronic transfusion and 
chelation. These children were recruited from the previously reported SWITCH study [2]. The 
primary endpoint of the study was to compare standard therapy (transfusions and chelation) with 
the alternative therapy (hydroxyurea and phlebotomy) in preventing secondary stroke and the 
reduction of transfusional iron overload in children with SS and previous stroke. The authors 
compared the rates of vaso-occlusive pain and other non-neurological adverse events such as 
acute chest syndrome, infection, infestation, etc. in each treatment arm. They showed that blood 
transfusion was more effective than hydroxyurea in reducing the painful episodes. In another 
article, also in this issue of the journal, Oliveros at al. [3] report pain experience in adolescents 
and adults (age 12-71 years) with thalassemia.  Although thalassemia is not typically associated 
with pain, the authors report that of the 252 participants, 56% reported pain at least once over the 
course of the study, with 32% reported severe pain. Additionally, the pain burden increased with 
increasing age in patients with thalassemia. Moreover, the report by Oliveros et al.[3] is an 
extension of a previous recent study demonstrating significant correlation (p < 0.001) of 
increased pain with increased age irrespective of diagnosis, gender, transfusion status, bone 
density or iron overload [4]. The effect of age on the frequency and severity of pain in SS, 
however, is not well studied and seems to be more complex. In one of  the Multicenter Study of 
Hydroxyurea in Sickle Cell Anemia (MSH) follow-up studies the utilization of analgesics at 
home (which is a surrogate measure of pain)  reached a peak at the age of 30-35 years and 
decreased after the age of 35 years especially in males . Moreover, in all the studies mentioned 
above, neuropathy and neuropathic pain were not mentioned, described or diagnosed thus raising 
the question whether they do not complicate SS and thalassemia or whether their diagnosis is 
missed. The known types of pain in patients with sickle cell disease (SCD) in general and SS in 
particular include the recurrent vaso-occlusive crises (VOC), the persistent pain between crises, 
chronic pain , pain due to therapy and pain due to co-morbid conditions. .Anecdotally, therapy 
with opioids may be occasionally associated with hyperalgesia associated with some neuropathic 
features.  Peripheral neuropathy has been described in SS but neuropathic pain has not been well 
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documented to date. This commentary will critically analyze this issue, review the definitions 
and describe the diagnostic criteria of neuropathy and neuropathic pain and their relation to SCD. 
 
During the American civil war Dr. Mitchell from Philadelphia described pain 
following peripheral nerve trauma and published detailed accounts of what he 
called causalgia among soldiers who suffered severe trauma often resulting in 
amputations which, in turn, were associated with phantom pain in the missing 
limb.  His findings are regarded as the first scientific approach to the study of the 
clinical features and pathophysiology of neuropathic pain.  Until recently 
neuropathic pain has been considered secondary to trauma only. In 1994 the 
International Association for the Study of Pain (IASP) defined neuropathic pain as 
“pain initiated or caused by a primary lesion, dysfunction, or transitory 
perturbation of the peripheral or central nervous system”. In 2011 neuropathic pain 
was redefined as “pain caused by a lesion or disease of the somatosensory system 
[5] Most important in this new definition is that the word dysfunction was removed 
and a specific disease or lesion in the nervous system has to be specified. There has 
been some disagreement about this restrictive definition that excludes fibromyalgia 
and complex regional pain syndrome (CRPS) from the neuropathic pain group and 
stigmatizes them as dysfunctional pain syndromes[5]. Whether more changes of 
the definition may evolve remains to be seen. 
 
Neuropathy and neuropathic pain are not synonymous and diabetic neuropathy, 
for example, is not always associated with pain. The prevalence of neuropathy 
among diabetics is 40-60% whereas neuropathic pain occurs in 10-16% of 
diabetics [6]. The presence or absence of neuropathy in diabetics is determined by 
a globally validated scale that includes the assessment of sensory modalities, 
muscle strength tests and reflexes on both sides of the body referred to as the 
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“diabetic  neuropathy 4 (DN4)” scale. A score > 4 in this scale indicates the 
presence of neuropathy. Another globally validated scale, the Leeds assessment of 
neuropathic symptoms and signs (LANSS) scale, is used to determine if diabetic 
neuropathy is painful or not; a score ≥ 12 on LANSS scale indicates the presence 
of painful neuropathy [7]. Unless these or other scales are validated for SCD, it is 
difficult to establish a firm diagnosis of neuropathic pain due to SCD. Suffice to 
say that patients with SCD who complain of burning, tingling, numbness, pins and 
needles and itching only may have neuropathy whereas those who have these 
symptoms and allodynia, hyperalgesia, and sensitivity to cold and heat may have 
neuropathic pain. Review of the literature showed reference to sickle neuropathy 
often but rarely to neuropathic pain [8]. 
 
Given that neuropathic pain describes disorders that involve aberrant 
somatosensory processing in the nervous system, a pathophysiologic classification 
divides these disorders into central and peripheral neuropathic pain. Both of these 
types of pain are rarely reported in association with SCD. This paucity of reports 
may represent an authentic low incidence or inability of care providers to 
differentiate neuropathic pain from the pain associated with the acute VOC typical 
of SCD. The current paradigm in pain literature is that persistent acute pain often 
results in chronic pain due to central sensitization and persistent chronic pain, in 
turn, may cause neuropathic pain possibly due to glial activation.  Sickle cell pain 
is presumed to follow this sequence pari passu but there are no studies to support 
this hypothesis. Additionally differences in pathophysiology does not support 
managing sickle cell pain the way other  pain syndromes are treated. 
Moreover, although there seems to be general consensus about the definition of 
acute and chronic pain, the definition of neuropathic falters and continues to 
change with time. 
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Novel approaches to determine neuropathic descriptors of sickle cell pain have 
been developed by Wilkie et al. [9]. They found significant overlap between 
nociceptive and neuropathic descriptors of pain in patients with SCD. Although 
their findings are preliminary, nevertheless, their methods may eventually lead to 
the establishment of tools to diagnose neuropathy and neuropathic pain in patients 
with SCD. Although neuropathic pain in patients with SCD is not well understood, 
its presence in the transgenic sickle mouse seems to be more convincing. Mice 
expressing sickle hemoglobin (Hb S) exhibited pain characteristics similar to those 
observed in patients with SCD [10]. Transgenic mice expressing various levels of 
Hb S demonstrated increase sensitivity to cold, heat, and mechanical stimuli and to 
deep tissue/musculoskeletal pain compared with their age-matched, controls. 
Hypoxia/reoxygenation further increased pain behaviors in these Hb S-expressing 
mice. Inflammatory mediators were markedly increased in the spinal cord of Hb S-
expressing mice compared with control mice expressing normal human 
hemoglobin. Thus, these changes support the existence of inflammatory and 
neuropathic pain in sickle mice. Studies of pain sensitivities in humans with SCD, 
however, yielded varying results. Brandow at al [11] found that children with SCD 
exhibit hypersensitivity to thermal stimuli suggesting that peripheral or central 
sensitization may exist and could contribute to SCD pain; O’Leary et al.[12], 
however, found no evidence that children with SCD had altered heat pain 
thresholds compared with controls. Additionally detection of pain thresholds were 
not associated with history of pain, gender or laboratory markers of hemolysis 
suggesting the need for more human studies. 
 
Central neuropathic pain, according to IASP, is caused by a lesion or 
dysfunction in the central nervous system . Given that SCD involves the CNS, we 
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would expect that central neuropathic pain might occur in this disease. However, 
except for acute headaches that may accompany cerebral hemorrhage or infection, 
central post-stroke pain is not reported in SCD. Neurological complications in 
SCD involving the CNS include cerebral infarction, intracranial hemorrhage, 
cognitive dysfunction, hearing loss, and a few cases of spinal cord infarction. The 
most striking neurological complication of SS is stroke due to cerebral infarction. 
The observed frequency varies from 6% to as high as 34%. If untreated, cerebral 
infarction may recur in two-thirds of affected patients. Central post-stroke pain has 
an estimated incidence of 8% of all strokes due to cerebrovascular accidents [13]. 
Reports of central post-stroke pain in SCD are absent from the literature. In fact, 
children who develop strokes due to sickle cell anemia and who are treated with 
chronic transfusion or exchange transfusion experience significant decrease (or 
even total absence) of painful episodes compared to their peers without stroke and 
without chronic transfusion. The reasons why post-stroke pain is not described in 
SCD are unknown. One possibility pertains to the location of the infarct, which 
usually involves the deep white matter or the cortex (Table I) and rarely involves 
the brain stem, the thalamus, or the spinal cord. Other possibilities include the 
difficulty in differentiating post-stroke pain from VOC and the prevention of 
further tissue damage and inflammation by the prompt initiation of therapy with 
blood transfusion or exchange transfusion. Moreover, in stroke and spinal cord 
injury, the onset of pain is often delayed unlike central pain due to other causes 
such as multiple sclerosis [13]. Thus in patients with SCD delayed central pain 
after a stroke may be easily ascribed to SCD rather to the stroke. Other types of 
central pain such as painful epileptic seizure, multiple sclerosis, Parkinson’s 
disease, and syringomyelia have not been described in association with sickle cell 
syndromes. 
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 Peripheral neuropathy and peripheral neuropathic pain result from damage to 
the peripheral nerves, plexus, dorsal root ganglion, or root. Hematologists are 
familiar with chemotherapy-induced peripheral neuropathy (CIPN) among patients 
with hematologic malignancies.  Its incidence varies from 10% - 100% among the 
different chemotherapeutic agents depending on the type of drug, dosage and 
pattern of administration .  The pathogenesis of CIPN is unknown. The coexistence 
of several mechanisms involving inflammation, direct cytotoxicity and deficiency 
in growth factors such as nerve growth factor (NGF) and brain-derived 
neurotrophic factor (BDNF) may be responsible for this syndrome . Hydroxyurea, 
a chemotherapeutic agent used in SCD has not been associated with peripheral 
neuropathy in patients with SCD. 
 
  The rarity of peripheral nerve infarction in SCD may be due to unusual 
anatomical and pathophysiological characteristics of the microvascular network 
that supplies peripheral nerves. Peripheral nerves receive their blood supply from 
the arteriae nervorum, which are of relatively larger diameter and form a rich and 
complex interconnecting network of nutrient vessels and may protect peripheral 
nerves from infarction because of its ability to maintain adequate blood circulation 
even if the patency of a primary nutrient vessel is compromised. Peripheral 
neuropathy in patients with SCD is not common. Table II lists the peripheral 
neuropathies that have been reported at least once in association with SCD.  
Electrophysiologic studies suggest that silent peripheral nerve involvement may 
precede overt clinical signs and symptoms. It may be possible for 
electrophysiological examinations to predict the diagnosis of peripheral neuropathy 
in patients with SCD prior to the onset of neurological signs and symptoms. The 
mental and mandibular neuropathies are the most commonly reported in patients 
with SCD. Mental nerve neuropathy has been reported in 10 patients with SS 
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between 1972 and 2012  Mandibular nerve neuropathy has been described in two 
patients one of whom had coexistent G6PD deficiency .  Lesions of the mental 
nerve are associated with numbness of the chin, often referred to as the numb chin 
syndrome, and are believed to result from bone compression due to mandibular 
bone infarction. Mental nerve neuropathy was more common in females and was 
bilateral in one patient. All reported episodes of mental nerve neuropathy occurred 
during VOC and resolved with the resolution of the VOC. 
 
 A cross-sectional Brazilian study [14] determined orofacial manifestations in 
150 patients with SS and compared them to 150 control subjects.  Patients with SS 
had significantly higher prevalence of previous mental nerve neuropathy (p = 
0.000) and delayed tooth eruption (p = 0.006) than controls.  Moreover, previous 
mental nerve neuropathy was more frequent among females and previous 
mandibular pain was more frequent among individuals older than 21 years.  
 
 A Nigerian study evaluated 613 patients with SS attending outpatient clinics 
and 616 control subjects to determine the prevalence of neurological complications 
in SS using a uniform structured questionnaire [15].  Neurological abnormalities 
occurred in significantly higher percentage of patients (76%) compared to controls 
(32.1%).  Among adolescents 38 out of 226 patients (16.8%) had localized sensory 
neuropathy and among adults12 out of 291 patients (4.1%) had localized sensory 
neuropathy.  The specific description and location of these neuropathies, however, 
were not mentioned.  Headache was significantly higher in children and 
adolescents compared to controls, but not in adult [15]. 
 
      A Turkish study determined peripheral nerve involvement 
electrophysiologically in 51 patients with SCD who were asymptomatic without 
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clinically evident neurological signs and symptom and compared them to 51 
control subjects.  Conventional electrophysiological studies of peripheral nerves 
were performed on all subjects [8].  Peripheral nervous system involvement was 
detected in 10 (19.6%) patients.  Five (9.8%) patients had sensorimotor axonal 
neuropathy, two (3.9%) had sensory axonal neuropathy, one (2%) had ulnar 
sensory neuropathy and two (3.9%) had median sensory neuropathy. These 
findings suggest that silent peripheral nerve involvement may precede overt 
clinical signs and symptoms.  Unfortunately, the authors did not follow these 
patients to determine if overt peripheral neuropathy develops in some or in all of 
them later on.  Nevertheless, this study suggests that electrophysiological 
examinations may predict the diagnosis of peripheral neuropathy in patients with 
SCD prior to the onset of neurological signs and symptoms. 
 
 
 In summary neuropathy and neuropathic pain are not the same and not all 
patients with neuropathy have pain. Neuropathic pain is not well documented as a 
complication of sickle cell disease. Neuropathy, especially peripheral neuropathy, 
has been reported in patients with sickle cell disease, albeit uncommonly. Mental 
nerve neuropathy (AKA numb chin syndrome) is the most commonly reported 
neuropathy in SCD usually associated with VOC. More studies are needed to 
determine the prevalence of neuropathy and neuropathic pain in patients with SCD 
and to find if these are complications of the disease itself or due to co-morbidities. 
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